July 13, 2021 -- Curia, formerly known as Albany Molecular Research (AMRI), has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.
Integrity Bio's biologic capabilities are complementary with Curia's existing business and will expand on biologic formulation and fill-finish commercial manufacturing capabilities it currently provides at three facilities in Albuquerque, NM; Burlington, MA; and Glasgow, Scotland, according to Curia. In addition, Integrity Bio will add West Coast coverage to Curia's East Coast and European capabilities, Curia said.
Subject to standard and customary closing conditions, the deal is expected to be completed in the third quarter. Terms of the agreements were not disclosed.